The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Duloxetine Versus Placebo for the Treatment of North American Women With Stress Urinary Incontinence
Abstract
PURPOSE: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, increases rhabdosphincter contractility via the stimulation of pudendal motor neuron alpha-1 adrenergic and 5-hydroxytryptamine-2 receptors. In this first phase 3 study we assessed the efficacy and safety of duloxetine in women with stress urinary incontinence (SUI). MATERIALS AND METHODS: A total of 683 North American women 22 to 84 years old were enrolled in this double-blind, placebo controlled study. The case definition included a predominant symptom of SUI with a weekly incontinence episode frequency (IEF) of 7 or greater, the absence of predominant symptoms of urge incontinence, normal diurnal and nocturnal frequency, a bladder capacity of 400 ml or greater, and a positive cough stress test and stress pad test. After a 2-week placebo lead-in period subjects were randomly assigned to receive placebo (339) or 80 mg duloxetine daily (344) as 40 mg twice daily for 12 weeks. Primary outcome variables included IEF and an incontinence quality of life questionnaire. Van Elteren's test was used to analyze percent changes in IEF with a stratification variable of weekly baseline IEF (less than 14 and 14 or greater). ANCOVA was used to analyze incontinence quality of life scores. RESULTS: Mean baseline IEF was 18 weekly and 436 subjects (64%) had a baseline IEF of 14 or greater. There was a significant decrease in IEF with duloxetine compared with placebo (50% vs 27%, p <0.001) with comparably significant improvements in quality of life (11.0 vs 6.8, p <0.001). Of subjects on duloxetine 51% had a 50% to 100% decrease in IEF compared with 34% of those on placebo (p <0.001). These improvements with duloxetine were associated with a significant increases in the voiding interval compared with placebo (20 vs 2 minutes, p <0.001) and they were observed across the spectrum of incontinence severity. The discontinuation rate for adverse events was 4% for placebo and 24% for duloxetine (p <0.001) with nausea the most common reason for discontinuation (6.4%). Nausea, which was also the most common side effect, tended to be mild to moderate and transient, usually resolving after 1 week to 1 month. Of the 78 women who experienced treatment emergent nausea while taking duloxetine 58 (74%) completed the trial. CONCLUSIONS: These phase 3 data are consistent with phase 2 data and they provide further evidence for the safety and efficacy of duloxetine as a pharmacological agent for the treatment of women with SUI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., & Wein, A. (2002) · Neurourology and Urodynamics · doi:10.1002/nau.10052 · Cited by 8,296
Abrams, P., Blaivas, J. G., Stanton, S. L., & Andersen, J. T. (1989) · World Journal of Urology · doi:10.1007/bf00328107 · Cited by 1,795
A community-based epidemiological survey of female urinary incontinence:
Hannestad, Y. S., Rortveit, G., Sandvik, H., & Hunskaar, S. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00232-8 · Cited by 1,326
Validation of two global impression questionnaires for incontinence
Yalcin, I., & Bump, R. C. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.379 · Cited by 887
Self-citationPhenylpropanolamine and the Risk of Hemorrhagic Stroke
Kernan, W. N., Viscoli, C. M., Brass, L. M., Broderick, J. P., Brott, T., Feldmann, E., Morgenstern, L. B., Wilterdink, J. L., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432501 · Cited by 611
Cost of pelvic organ prolapse surgery in the United States
Subak, L. (2001) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(01)01472-7 · Cited by 532
Patrick, D. L., Martin, M. L., Bushnell, D. M., Yalcin, I., Wagner, T. H., & Buesching, D. P. (1999) · Urology · doi:10.1016/s0090-4295(98)00454-3 · Cited by 509
Self-citationDefinition of overactive bladder and epidemiology of urinary incontinence
Hampel, C., Wienhold, D., Benken, N., Eggersmann, C., & Thüroff, J. W. (1997) · Urology · doi:10.1016/s0090-4295(97)00578-5 · Cited by 375
Duloxetine versus placebo in the treatment of stress urinary incontinence
Norton, P. A., Zinner, N. R., Yalcin, I., & Bump, R. C. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.124840 · Cited by 331
Self-citationThor, K. B., & Katofiasc, M. A. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10548-x · Cited by 311
Cited by
Andersson, K.-E., & Wein, A. J. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.4 · Cited by 484
Integrative control of the lower urinary tract: preclinical perspective
de Groat, W. C. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706604 · Cited by 405
Shamliyan, T. A., Kane, R. L., Wyman, J., & Wilt, T. J. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-6-200803180-00211 · Cited by 281
Imamura, M., Abrams, P., Bain, C., Buckley, B., Cardozo, L., Cody, J., Cook, J., Eustice, S., Glazener, C., Grant, A., et al. (2010) · Health Technology Assessment · doi:10.3310/hta14400 · Cited by 254
Abraha, I., Cherubini, A., Cozzolino, F., De Florio, R., Luchetta, M. L., Rimland, J. M., Folletti, I., Marchesi, M., Germani, A., Orso, M., et al. (2015) · BMJ · doi:10.1136/bmj.h2445 · Cited by 165
Metadata
- Authors
- DMOCHOWSKI, R. R., MIKLOS, J. R., NORTON, P. A., ZINNER, N. R., YALCIN, I., BUMP, R. C., & for the DULOXETINE URINARY INCONTINENCE STUDY GROUP
- Venue
- Journal of Urology
- Published
- 2003-10
- Volume
- 170
- Issue
- 4 Part 1
- Pages
- 1259-1263
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2115562984
- Cited by
- 302
- References
- 13
- FWCI
- 23.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duloxetine Versus Placebo for the Treatment of North American Women With Stress Urinary Incontinence. https://app.cochat.ai/papers/10.1097/01.ju.0000080708.87092.cc
- The paper
- DMOCHOWSKI, R. R., MIKLOS, J. R., NORTON, P. A., ZINNER, N. R., YALCIN, I., BUMP, R. C., & for the DULOXETINE URINARY INCONTINENCE STUDY GROUP. (2003). Duloxetine Versus Placebo for the Treatment of North American Women With Stress Urinary Incontinence. Journal of Urology. https://doi.org/10.1097/01.ju.0000080708.87092.cc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.